PHT Corporation Achieves Strong Growth in 3rd Quarter as Demand for Patient-Driven eData Systems in Clinical Research Grows

PHT Corporation Achieves Strong Growth in 3rd Quarter as Demand for Patient-Driven eData Systems in Clinical Research Grows

Quarterly bookings increase by 97% over Q3 2013 as the PHT eCOA System is chosen for 20 industry sponsored clinical trials and studies

October 30, 2014

BOSTON & GENEVA--()--PHT Corporation third-quarter bookings climbed sharply, 97% over the same period in 2013 as more trial sponsors and CROs adopted its eCOA Systems to collect patient-driven eData for clinical research programs.

The PHT eCOA System was chosen by 12 different pharmaceutical and biotech clients to collect patient-driven eData for 20 clinical research programs in 11 therapeutic areas. PHT is seeing strong demand for eCOA Systems across therapeutic areas with adoption increasing greatly in oncology, immunology and endocrinology indications along with respiratory and neurology. Sales were both direct to customer and through CRO partnerships.

Demand for PHT Clinical Science and Consulting Services reached an all-time high as sponsors now require a broader range of services from eCOA providers. PHT Scientists work collaboratively with sponsors and outcomes researchers to ensure instruments are appropriate for electronic platforms, meet trial participant and clinician needs and match regulatory expectations.

PHT President and CEO Philip Lee said, "Sponsors and CROs have chosen PHT for over 675 clinical trials because they recognize that paper diaries are inadequate for supporting their needs and want to realize the many benefits of using an eCOA System to collect accurate patient data. PHT is well positioned for continued growth with a world-class team committed to maximizing customer value and convenience."

Additional Q3 highlights included:

  • Vice President of Clinical Science and Consulting Services Dr. Susan Dallabrida is one of this year's PharmaVOICE 100 most inspiring people in life sciences.
  • Industry Recognition – The PHT Patient Connect™ Engagement App which makes participating in clinical studies easier for patients was one of only three finalists for the 2014 SCDM Technology Innovation Award.
  • PHT was named among the Boston Business Journal's list of the area's 100 largest private companies for the third time.

About PHT Corporation

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in over 675 trials resulting in 21 regulatory approvals. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Facebook, Twitter, Google+ and YouTube.

Contacts

Media contact:
For PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]m

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.